Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03298477 · ClinicalTrials.gov registry record · NA

EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study

A NA study of Abdominal Aortic Aneurysm Without Rupture, sponsored by Endologix.

Active
Registry status
NA
Development phase
98
Enrollment target
20
Study locations

NCT03298477 is a NA study of Abdominal Aortic Aneurysm Without Rupture that is active but no longer recruiting, run by Endologix. The registered enrollment target is 98 participants. The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03298477, a NA study of Abdominal Aortic Aneurysm Without Rupture, is active but no longer recruiting, sponsored by Endologix.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
98 participants
Enrollment target
20
Study locations

Study Summary

Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.

Interventions

  • DEVICE Nellix® System

Study Locations (20)

Florida

  • Miami Cardiac & Vascular Institute (MCVI) - Miami
  • AdventHealth Orlando - Orlando
  • Coastal Vascular & Interventional - Pensacola

California

  • Regents of the University of California (UCLA) - Los Angeles
  • Veterans Medical Research Foundation - San Diego

Illinois

  • Christie Clinic - Champaign
  • AMITA Health - Elk Grove Village

Ohio

  • Cleveland Clinic - Cleveland
  • Northeast Ohio Vascular Assoc (NEOVA) - Willoughby

Alabama

  • Valley Vascular Consultants - Huntsville

Colorado

  • UC Health-Memorial Hospital - Colorado Springs

District of Columbia

  • MedStar Health Research Institute - Washington D.C.

Indiana

  • St. Vincent Heart Center of Indiana - Indianapolis

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2017-12-01
Est. Completion 2025-08-16
Phase NA

Sponsor

Endologix

17 total trials

What the Registry Record Tells You About NCT03298477

The ClinicalTrials.gov registry entry for NCT03298477 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endologix, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Abdominal Aortic Aneurysm Without Rupture appearing as the primary indexed condition, and to 1 intervention - of which Nellix® System is the first listed.

NCT03298477 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT03298477 about?

NCT03298477 is a clinical study titled "EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study". Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.

What is the current status of trial NCT03298477?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 98 participants. The study started on 2017-12-01. Estimated completion is 2025-08-16.

What conditions does trial NCT03298477 study?

This clinical trial studies the following conditions: Abdominal Aortic Aneurysm Without Rupture.

What interventions are being tested in trial NCT03298477?

The interventions under investigation include: Nellix® System (DEVICE).

Who is sponsoring clinical trial NCT03298477?

This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03298477 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.